MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
MYX - MAYNE PHARMA GROUP LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.39
Index: ASX300 | ALL-ORDS
Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$5.86
06 Dec |
OPEN $5.46 |
HIGH $5.90 |
257,615 LOW $5.46 |
0.310| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MXC . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -385.1 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 54.4 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 183.6 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 760.4 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -43.1 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -172.86 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -52.93 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -51.27 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -24.88 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -52.93 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -22.56 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -96.8 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 14 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 33 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 48 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 229 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 0.58 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 219.6 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 119.61 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 157 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 213 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 16 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
MYX STOCK CHART
FNArena News on MYX
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
| 2 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
| 3 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
| 4 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |
| 5 |
Breaking Boundaries: Medical PsychedelicsAug 21 2023 - Small Caps |
| 6 |
Momentum Keeps Building For Avita MedicalAug 15 2023 - Small Caps |
| 7 |
Dr Boreham’s Crucible: IDT AustraliaAug 14 2023 - Small Caps |
| 8 |
Treasure Chest: Less Smooth Road Ahead For CSLAug 01 2023 - Treasure Chest |
| 9 |
Dr Boreham’s Crucible: Telix PharmaceuticalsJul 31 2023 - Small Caps |
| 10 |
Dr Boreham’s Crucible: Arovella TherapeuticsJul 17 2023 - Small Caps |
